Over the years, Samuel Deng has been dedicated to non-litigation and litigation legal services in the fields of finance and asset management, investment and M&A, securities, and guarantees. He has also delved into the life sciences and pharmaceuticals, culture, tourism, and hotels industries. He has provided legal services to numerous financial institutions, including banks, securities firms, fund management companies, and trust companies, domestic and overseas listed companies, state-owned enterprises, pharmaceutical companies, grade 3A hospitals, and top-tier biotech companies, accumulating rich practical experience.
In the financial sector, especially in asset management, Samuel has established close cooperative relations with many asset management institutions, including asset management subsidiaries of securities companies, fund management companies, trust companies, and private fund managers. He has a deep understanding of the regulatory systems and rules of the financial, securities, and general asset management industries. He is adept at designing complex transaction structures, negotiations, core legal issues, and drafting related transaction documents for financial products, and has extensive experience in providing whole course legal services for asset management product on fundraising, establishment, investment, management, and withdrawal.
In the fields of biological sciences, pharmaceutical healthcare, Samuel Deng has long served leading domestic gene-editing biotech companies, research-oriented tertiary hospitals, and internet-based healthcare platforms. He has provided comprehensive legal services for investment and M&A transactions involving numerous pharmaceutical manufacturers, pharmaceutical distribution companies, and pharmaceutical retailers. Samuel Deng also possesses substantial experience in areas including drug R&D, industry-academia-research collaboration in healthcare and pharmaceuticals, achievement transformation and commercialization, healthcare data management and compliance, as well as medical ethics.
In the corporate and commercial field, especially in investment and M&A, Samuel has led many large and complex investment and M&A transactions with industry influence and representativeness. The types of mergers and acquisitions include restructuring and listing, acquisition of controlling rights of listed companies, mergers and acquisitions of state-owned enterprise and foreign-invested enterprises, and industrial mergers and acquisitions. He expertises at designing reasonable transaction structures to effectively guard clients against risks and help clients achieve their business objectives. Samuel has provided wholecourse legal services for investment and M&A transactions, including legal due diligence, deal structuring, transaction document drafting, negotiation, equity and asset delivery, and post-investment management.
In the field of dispute resolution, Samuel Deng has represented clients in numerous complex, high-value litigation and arbitration cases involving asset management, securities, and investment financing. These cases have been adjudicated before courts including the Supreme People’s Court, High People’s Courts, and Financial Courts. The types of cases involve fraudulent issuance and securities misrepresentation, asset manager liability, investment advisor liability, bond trading, and pledge-style share repurchase transactions. Through diversified dispute resolution methods, he has achieved effective risk management outcomes.
"Outstanding Member of the Year" by the Mergers and Acquisitions Research Committee of the Shanghai Bar Association for four consecutive years from 2020 to 2023.
"2022 ALB China Regional Ranking: “Yangtze River Delta Rising Lawyers" by Asian Legal Business in 2022
"Top Ten Lawyers" and "Outstanding Lawyer" of Changning District, Shanghai from 2013 to 2016.
Deputy Director of the Mergers and Acquisitions Research Committee of the Shanghai Bar Association
Pro Bono Lawyer of the China Securities Investor Services Center
Member of Specialized Subcommittee on Medical Research Ethics, Shanghai Medical Association
Member of Specialized Committee on Clinical Research Ethics, Shanghai Research Hospital Association
Member of the Ethics Committee of Huashan Hospital of Fudan University
Arbitrator of Guiyang Arbitration Commission
Adjunct Professor at the School of Law, East China University of Science and Technology
Practicum Supervisor at Law School of Tongji University
May 2024 to Present, SGLA Law Firm Shanghai Office, Senior Partner.
January 2018 to May 2024, Beijing W&H Law Firm Shanghai Office, Senior Partner.
August 2015 to December 2017, Beijing W&H Law Firm Shanghai Office, Partner.
February 2012 to August 2015, AllBright Law Office, Lawyer.
-In the field of financial asset management, as a legal advisor to many securities companies, securities asset management companies, fund management companies and their subsidiaries, trust companies, and private fund managers, providing wholecourse legal services for their daily operations, risk disposal, litigation and arbitration.
-In the field of culture, tourism, and hotels, as a long-term legal advisor for the mergers and acquisitions of the leading OTA platform, providing whole course legal services to build a multi-field and multi-chain cultural tourism business layout, including the acquisitions of well-known hotel management companies, travel agencies, airlines, cruise companies, and scenic area operation companies.
-In the pharmaceutical field, as a dedicated legal advisor for numerous renowned large enterprises such as a listed pharmaceutical company, a Shandong-based pharmaceutical manufacturer, and an industrial finance company, he has provided full-range legal services for a series of investment and M&A projects across upstream and downstream industrial chains. These projects involve pharmaceutical companies specializing in biologicals, chemical generics, and traditional Chinese medicine preparations, as well as pharmacy chains..
-In the healthcare field, as a perennial legal advisor to the nationally renowned research-oriented tertiary hospital and its subsidiaries, providing comprehensive legal services for its technology transfer, regional medical center construction and cooperation within integrated health care systems, Internet medical and hierarchical diagnosis and treatment, donations, investment and financing, and asset management, etc., as a legal expert, he serves as a member of the Ethics Committee, conducting ethical reviews for its clinical research/trial projects.
-In the field of biotech, as a legal advisor to the first precise gene editing engineering research, development and industrialization platform company in China, providing comprehensive legal services for its patent acquisition/license and authorization, technology export, establishment of overseas subsidiaries, gene editing industrialization, introduction of multiple rounds of strategic investors, construction of gene editing public technology platforms, employee equity incentive, compliance system construction, and other important projects.
-"Chinese Guarantee Law Regulatory Compilation and Case Selection (Annotated Edition)", published by Peking University Press in May 2019.
-"Major Changes You Need to Know in the Guarantee Field in the Era of the Civil Code", published in the October 1, 2020 issue of "China Guarantee".
-"Asset Management & Securities Annual Review (2022)," published on the WeChat public account "Financial Law Insight"
-"Asset Management & Securities Annual Review (2023)," published on the WeChat public account "Financial Law Insight"
-"Asset Management & Securities Annual Review (2024)," published on the WeChat public account "Financial Law Insight"
-"Illustrated M&A" series with 12 articles, published on the WeChat public account "Financial Law Insight" from 2019 to 2021; and as the main speaker, Samuel conducted the corresponding lectures at the Shanghai Bar Association.
-"Empirical Analysis of the Nature of Asset Management Legal Relations under the New Regulatory Background", included in the proceedings of the 4th Cross-Strait Trust Legal Studies Seminar.
-"Impact of the New Asset Management Regulation and Associated Rules on Securities Asset Management", included in the proceedings of the 3rd Cross-Strait Trust Legal Studies Seminar.
-"Research on the Issue of Bondholders' Individual Right to Sue", published on Legal Daily in February 2019.
-"How to Calculate Investment Losses under the New Securities Law for False Statements", included in the Wolters Kluwer Legal Information Database in 2020.
-"Q&A on Legal Practice in Hotel Investment and Operations" Article Series, published on the WeChat public account "Financial Law Insight" in 2024
-"Interpretation of Core Points of the Regulations on Non-Bank Payment Institutions (Draft for Comments)", published in the first issue of "Shanghai Lawyer" in 2023.
-"Exploring the 'One Participation, One Control' Rule for Non-Bank Payment Institutions Under the New Payment Regulations," included in the Wolters Kluwer Legal Information Database in 2025.
Over the years, Samuel Deng has been dedicated to non-litigation and litigation legal services in the fields of finance and asset management, investment and M&A, securities, and guarantees. He has also delved into the life sciences and pharmaceuticals, culture, tourism, and hotels industries. He has provided legal services to numerous financial institutions, including banks, securities firms, fund management companies, and trust companies, domestic and overseas listed companies, state-owned enterprises, pharmaceutical companies, grade 3A hospitals, and top-tier biotech companies, accumulating rich practical experience.
In the financial sector, especially in asset management, Samuel has established close cooperative relations with many asset management institutions, including asset management subsidiaries of securities companies, fund management companies, trust companies, and private fund managers. He has a deep understanding of the regulatory systems and rules of the financial, securities, and general asset management industries. He is adept at designing complex transaction structures, negotiations, core legal issues, and drafting related transaction documents for financial products, and has extensive experience in providing whole course legal services for asset management product on fundraising, establishment, investment, management, and withdrawal.
In the fields of biological sciences, pharmaceutical healthcare, Samuel Deng has long served leading domestic gene-editing biotech companies, research-oriented tertiary hospitals, and internet-based healthcare platforms. He has provided comprehensive legal services for investment and M&A transactions involving numerous pharmaceutical manufacturers, pharmaceutical distribution companies, and pharmaceutical retailers. Samuel Deng also possesses substantial experience in areas including drug R&D, industry-academia-research collaboration in healthcare and pharmaceuticals, achievement transformation and commercialization, healthcare data management and compliance, as well as medical ethics.
In the corporate and commercial field, especially in investment and M&A, Samuel has led many large and complex investment and M&A transactions with industry influence and representativeness. The types of mergers and acquisitions include restructuring and listing, acquisition of controlling rights of listed companies, mergers and acquisitions of state-owned enterprise and foreign-invested enterprises, and industrial mergers and acquisitions. He expertises at designing reasonable transaction structures to effectively guard clients against risks and help clients achieve their business objectives. Samuel has provided wholecourse legal services for investment and M&A transactions, including legal due diligence, deal structuring, transaction document drafting, negotiation, equity and asset delivery, and post-investment management.
In the field of dispute resolution, Samuel Deng has represented clients in numerous complex, high-value litigation and arbitration cases involving asset management, securities, and investment financing. These cases have been adjudicated before courts including the Supreme People’s Court, High People’s Courts, and Financial Courts. The types of cases involve fraudulent issuance and securities misrepresentation, asset manager liability, investment advisor liability, bond trading, and pledge-style share repurchase transactions. Through diversified dispute resolution methods, he has achieved effective risk management outcomes.
Juris Master, Fudan University
LL.B., China University of Political Science and Law
"Outstanding Member of the Year" by the Mergers and Acquisitions Research Committee of the Shanghai Bar Association for four consecutive years from 2020 to 2023.
"2022 ALB China Regional Ranking: “Yangtze River Delta Rising Lawyers" by Asian Legal Business in 2022
"Top Ten Lawyers" and "Outstanding Lawyer" of Changning District, Shanghai from 2013 to 2016.
Deputy Director of the Mergers and Acquisitions Research Committee of the Shanghai Bar Association
Pro Bono Lawyer of the China Securities Investor Services Center
Member of Specialized Subcommittee on Medical Research Ethics, Shanghai Medical Association
Member of Specialized Committee on Clinical Research Ethics, Shanghai Research Hospital Association
Member of the Ethics Committee of Huashan Hospital of Fudan University
Arbitrator of Guiyang Arbitration Commission
Adjunct Professor at the School of Law, East China University of Science and Technology
Practicum Supervisor at Law School of Tongji University
May 2024 to Present, SGLA Law Firm Shanghai Office, Senior Partner.
January 2018 to May 2024, Beijing W&H Law Firm Shanghai Office, Senior Partner.
August 2015 to December 2017, Beijing W&H Law Firm Shanghai Office, Partner.
February 2012 to August 2015, AllBright Law Office, Lawyer.
-In the field of financial asset management, as a legal advisor to many securities companies, securities asset management companies, fund management companies and their subsidiaries, trust companies, and private fund managers, providing wholecourse legal services for their daily operations, risk disposal, litigation and arbitration.
-In the field of culture, tourism, and hotels, as a long-term legal advisor for the mergers and acquisitions of the leading OTA platform, providing whole course legal services to build a multi-field and multi-chain cultural tourism business layout, including the acquisitions of well-known hotel management companies, travel agencies, airlines, cruise companies, and scenic area operation companies.
-In the pharmaceutical field, as a dedicated legal advisor for numerous renowned large enterprises such as a listed pharmaceutical company, a Shandong-based pharmaceutical manufacturer, and an industrial finance company, he has provided full-range legal services for a series of investment and M&A projects across upstream and downstream industrial chains. These projects involve pharmaceutical companies specializing in biologicals, chemical generics, and traditional Chinese medicine preparations, as well as pharmacy chains..
-In the healthcare field, as a perennial legal advisor to the nationally renowned research-oriented tertiary hospital and its subsidiaries, providing comprehensive legal services for its technology transfer, regional medical center construction and cooperation within integrated health care systems, Internet medical and hierarchical diagnosis and treatment, donations, investment and financing, and asset management, etc., as a legal expert, he serves as a member of the Ethics Committee, conducting ethical reviews for its clinical research/trial projects.
-In the field of biotech, as a legal advisor to the first precise gene editing engineering research, development and industrialization platform company in China, providing comprehensive legal services for its patent acquisition/license and authorization, technology export, establishment of overseas subsidiaries, gene editing industrialization, introduction of multiple rounds of strategic investors, construction of gene editing public technology platforms, employee equity incentive, compliance system construction, and other important projects.
-"Chinese Guarantee Law Regulatory Compilation and Case Selection (Annotated Edition)", published by Peking University Press in May 2019.
-"Major Changes You Need to Know in the Guarantee Field in the Era of the Civil Code", published in the October 1, 2020 issue of "China Guarantee".
-"Asset Management & Securities Annual Review (2022)," published on the WeChat public account "Financial Law Insight"
-"Asset Management & Securities Annual Review (2023)," published on the WeChat public account "Financial Law Insight"
-"Asset Management & Securities Annual Review (2024)," published on the WeChat public account "Financial Law Insight"
-"Illustrated M&A" series with 12 articles, published on the WeChat public account "Financial Law Insight" from 2019 to 2021; and as the main speaker, Samuel conducted the corresponding lectures at the Shanghai Bar Association.
-"Empirical Analysis of the Nature of Asset Management Legal Relations under the New Regulatory Background", included in the proceedings of the 4th Cross-Strait Trust Legal Studies Seminar.
-"Impact of the New Asset Management Regulation and Associated Rules on Securities Asset Management", included in the proceedings of the 3rd Cross-Strait Trust Legal Studies Seminar.
-"Research on the Issue of Bondholders' Individual Right to Sue", published on Legal Daily in February 2019.
-"How to Calculate Investment Losses under the New Securities Law for False Statements", included in the Wolters Kluwer Legal Information Database in 2020.
-"Q&A on Legal Practice in Hotel Investment and Operations" Article Series, published on the WeChat public account "Financial Law Insight" in 2024
-"Interpretation of Core Points of the Regulations on Non-Bank Payment Institutions (Draft for Comments)", published in the first issue of "Shanghai Lawyer" in 2023.
-"Exploring the 'One Participation, One Control' Rule for Non-Bank Payment Institutions Under the New Payment Regulations," included in the Wolters Kluwer Legal Information Database in 2025.